Newlands ES - Search Results

1

Calvert AH, Horwich A, Newlands ES, Begent R, Rustin GJ, Kaye SB, Harris AL, Williams CJ, Slevin ML. Calvert AH, et al. Among authors: newlands es. Lancet. 1988 Sep 3;2(8610):577-8. doi: 10.1016/s0140-6736(88)92709-2. Lancet. 1988. PMID: 2900968 No abstract available.

2

Pneumocystis carinii pneumonia and high-dose dexamethasone to prevent emesis of chemotherapy.

McCormack K, Rustin GJ, Smith DB, Newlands ES. McCormack K, et al. Among authors: newlands es. Lancet. 1991 Oct 12;338(8772):946-7. doi: 10.1016/0140-6736(91)91812-9. Lancet. 1991. PMID: 1681289 No abstract available.

3

Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy.

Smith DB, Newlands ES, Rustin GJ, Begent RH, Howells N, McQuade B, Bagshawe KD. Smith DB, et al. Among authors: newlands es. Lancet. 1991 Aug 24;338(8765):487-90. doi: 10.1016/0140-6736(91)90555-4. Lancet. 1991. PMID: 1714532 Clinical Trial.

4

Phase I-II study of carboplatin vincristine methotrexate and bleomycin (COMB) in carcinoma of the cervix.

Rustin GJ, Newlands ES. Rustin GJ, et al. Among authors: newlands es. Br J Cancer. 1988 Dec;58(6):818-9. doi: 10.1038/bjc.1988.317. Br J Cancer. 1988. PMID: 2465019 Free PMC article.

5

Cytotoxic drugs and sterility.

Rustin GJ, Bagshawe KD, Newlands ES, Begent RH. Rustin GJ, et al. Among authors: newlands es. Lancet. 1981 Jun 13;1(8233):1316. doi: 10.1016/s0140-6736(81)92488-0. Lancet. 1981. PMID: 6112631 No abstract available.

6

Chemotherapy for germ-cell tumours.

Newlands ES, Begent RH, Rustin GJ, Bagshawe KD. Newlands ES, et al. Lancet. 1983 Jul 16;2(8342):163. doi: 10.1016/s0140-6736(83)90145-9. Lancet. 1983. PMID: 6135007 No abstract available.

7

A phase I/II study of the 5-HT3 antagonist GR38032F in the anti-emetic prophylaxis of patients receiving high-dose cisplatin chemotherapy.

Smith DB, Newlands ES, Rustin GJ, Begent RH, Crawford SM, Bagshawe KD, Carruthers L. Smith DB, et al. Among authors: newlands es. Cancer Chemother Pharmacol. 1990;25(4):291-4. doi: 10.1007/BF00684888. Cancer Chemother Pharmacol. 1990. PMID: 1688516

8

What sort of oncology team should treat testicular teratoma?

Bagshawe KD, Begent RH, Newlands ES, Rustin GJ. Bagshawe KD, et al. Among authors: newlands es. Lancet. 1985 Apr 20;1(8434):930. doi: 10.1016/s0140-6736(85)91704-0. Lancet. 1985. PMID: 2858773 No abstract available.

9

Further advances in the management of malignant teratomas of the testis and other sites.

Newlands ES, Begent RH, Rustin GJ, Parker D, Bagshawe KD. Newlands ES, et al. Lancet. 1983 Apr 30;1(8331):948-51. doi: 10.1016/s0140-6736(83)92079-2. Lancet. 1983. PMID: 6188011

10

Treatment of good-risk, stage II, non-seminomatous testis cancer.

Boshoff C, Rustin G, Begent R, Oliver T, Newlands E, Holden L, Ong J. Boshoff C, et al. Lancet. 1994 Oct 15;344(8929):1085-6. doi: 10.1016/s0140-6736(94)91740-x. Lancet. 1994. PMID: 7934464 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

226 results

Search Page